Nivalis Therapeutics, Inc. (ALPN) Now Covered by Analysts at Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services started coverage on shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) in a report released on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $17.00 price objective on the biotechnology company’s stock.
ALPN has been the topic of several other research reports. Cowen and Company restated a hold rating on shares of Nivalis Therapeutics in a report on Wednesday, April 19th. Zacks Investment Research upgraded Nivalis Therapeutics from a hold rating to a buy rating and set a $3.00 target price on the stock in a report on Wednesday, April 19th. Finally, ValuEngine cut Nivalis Therapeutics from a sell rating to a strong sell rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of Hold and an average target price of $8.81.
Shares of Nivalis Therapeutics (NASDAQ ALPN) opened at 9.14 on Thursday. Nivalis Therapeutics has a 12-month low of $8.00 and a 12-month high of $37.40. The company has a 50-day moving average of $9.32 and a 200 day moving average of $9.82.
WARNING: This report was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/nivalis-therapeutics-inc-alpn-now-covered-by-analysts-at-ladenburg-thalmann-financial-services/1463557.html.
In other news, Director Robert E. Conway purchased 20,000 shares of the firm’s stock in a transaction that occurred on Friday, May 5th. The shares were acquired at an average price of $2.30 per share, for a total transaction of $46,000.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at $92,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Value Fund L. P. Biotechnology purchased 17,806 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $40,063.50. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 457,998 shares of company stock worth $1,051,354. 3.00% of the stock is owned by company insiders.
Nivalis Therapeutics Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.